Efficacy and Safety of Adding Sitagliptin in Type 2 Diabetes Patients on Insulin: Age-Stratified Comparison at One Year in the ASSIST-K Study

BACKGROUND: Sitagliptin, the first dipeptidyl peptidase-4 inhibitor, has demonstrated efficacy and safety as monotherapy and as add-on therapy to oral antidiabetic agents or insulin. However, there have been few reports about sitagliptin in elderly patients. The ASSIST-K observational study was perf...

Descripción completa

Detalles Bibliográficos
Autores principales: Takai, Masahiko, Ishikawa, Masashi, Maeda, Hajime, Kanamori, Akira, Kubota, Akira, Amemiya, Hikaru, Iizuka, Takashi, Iemitsu, Kotaro, Iwasaki, Tomoyuki, Uehara, Goro, Umezawa, Shinichi, Obana, Mitsuo, Kaneshige, Hideaki, Kaneshiro, Mizuki, Kawata, Takehiro, Sasai, Nobuo, Saito, Tatsuya, Takuma, Tetsuo, Takeda, Hiroshi, Tanaka, Keiji, Nakajima, Shigeru, Hoshino, Kazuhiko, Honda, Shin, Machimura, Hideo, Matoba, Kiyokazu, Minagawa, Fuyuki, Minami, Nobuaki, Miyairi, Yukiko, Mokubo, Atsuko, Motomiya, Tetsuya, Waseda, Manabu, Miyakawa, Masaaki, Terauchi, Yasuo, Tanaka, Yasushi, Matsuba, Ikuro
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Elmer Press 2019
Materias:
Original Article
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469892/
https://www.ncbi.nlm.nih.gov/pubmed/31019624
http://dx.doi.org/10.14740/jocmr3677

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6469892/
https://www.ncbi.nlm.nih.gov/pubmed/31019624
http://dx.doi.org/10.14740/jocmr3677

Ejemplares similares